TICKERNERD
Menu
ELVELVHealthcare · Healthcare Plans

ELV Stock Forecast: Elevance Health, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$383
+1.84% on the day

The 22 Wall Street analysts covering Elevance Health, Inc. hold a median 12-month price target of $457 — +19.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$81.5B
Ticker Nerd rank
62 / 100
Median analyst target
$457
Analysts covering
22
Total return, dividends reinvested
1W
+1.2%
1M
−8.4%
YTD
+10.3%
1Y
+42.3%
From 52W high
−10.3%
From 52W low
+42.1%
$269
$427
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Elevance Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
90
Value
89
Issuance
74
Revisions
69
Momentum
57
Growth
54
Quality
42
Accruals
37
Size
3

Volatility (90): The share price has been relatively steady.

Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Elevance Health, Inc. — and when they’d sell — is the membership.

Wall Street

ELV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400$450$500Oct 25Jan 26Apr 26Jul 26ELVHigh $492Median $457Low $393

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says22 analysts
15 Buy7 Hold0 Sell
Low $393Median $457High $492

The green dot is the last close — the median target sits +19.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
17 July 2026Leerink PartnersMaintainsMarket Perform$364 → $395
16 July 2026BairdMaintainsNeutral$331 → $393
16 July 2026BarclaysMaintainsOverweight$480 → $457
16 July 2026GuggenheimMaintainsBuy$399 → $455
16 July 2026RBC CapitalMaintainsSector Perform$439 → $424
16 July 2026Wells FargoMaintainsOverweight$492 → $473
14 July 2026TD CowenMaintainsBuy$400 → $465
14 July 2026Truist SecuritiesMaintainsBuy$450 → $475
13 July 2026Wells FargoMaintainsOverweight$391 → $492
9 July 2026RBC CapitalMaintainsSector Perform—
9 July 2026RBC CapitalMaintainsSector Perform$358 → $439
7 July 2026Cantor FitzgeraldMaintainsOverweight$400 → $450
7 July 2026Cantor FitzgeraldMaintainsOverweight—
2 July 2026BernsteinMaintainsOutperform—
8 June 2026JP MorganMaintainsOverweight—
8 June 2026MizuhoMaintainsOutperform—
4 June 2026B of A SecuritiesMaintainsBuy—
4 June 2026Morgan StanleyMaintainsEqual-Weight—
1 June 2026Truist SecuritiesMaintainsBuy—
26 May 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ELV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.8%
Analysts raising
0
Analysts cutting
0
Fundamentals

Elevance Health, Inc. (ELV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.6×

Cheaper than 44% of US stocks

Price / sales
0.4×

Cheaper than 85% of US stocks

Price / book
1.8×

Cheaper than 48% of US stocks

EV / EBITDA
9.0×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
1.4%

Higher than 32% of US stocks

Earnings growth (YoY)
−16.1%

Higher than 22% of US stocks

Gross margin
—
Operating margin
4.6%

Higher than 57% of US stocks

Net margin
2.5%

Higher than 53% of US stocks

Returns & dividend
Return on equity
11.1%

Higher than 67% of US stocks

Return on assets
3.8%

Higher than 70% of US stocks

Dividend yield
1.8%

Higher than 42% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ELV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
ELVElevance Health, Inc.$81.5B
62
CIThe Cigna Group$73.8B
53
CVSCVS Health Corp.$132.6B
83
HUMHumana, Inc.$43.8B
44
CNCCentene Corp.$30.6B
89
UNHUnitedHealth Group, Inc.$375.4B
77
MOHMolina Healthcare, Inc.$10.1B
30
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ELV news & analysis

Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey

Business Wire · 30 July 2026positive

Elevance Health announced enhancements to its connected cancer care model, aimed at providing earlier support, personalized care navigation, and more coordinated care for consumers throughout their cancer journeys.

Why it matters — This initiative could strengthen Elevance's value proposition in the healthcare market by addressing a significant, emotionally and logistically complex area of patient care.

Oakmark U.S. Large Value Strategy Q2 2026 Portfolio Review

Seeking Alpha · 29 July 2026neutral

The Oakmark U.S. Large Value Strategy's Q2 2026 portfolio review discusses Delta Air Lines as a contributor despite fuel price headwinds from the Iran War, a decline in Intercontinental Exchange stock price due to AI disruption concerns, and a new position in Equitable Holdings. No mention of Elevance Health (ELV) appears in the report.

Why it matters — ELV watchers would note that the Oakmark strategy review contains no information directly relevant to Elevance Health, as the discussion focuses on other portfolio holdings.

GreensKeeper Value Fund Q2 2026 Portfolio Update

Seeking Alpha · 27 July 2026neutral

The GreensKeeper Value Fund's Q2 2026 portfolio update does not mention Elevance Health, Inc. The fund noted ICON plc as its top performer and Intercontinental Exchange as its largest detractor, with no major portfolio changes made during the quarter.

Why it matters — ELV watchers would note that the fund's update contains no new information or positioning changes regarding Elevance Health.

Billionaire Investor Seth Klarman's Top 5 Stocks: Would He Buy More Today?

24/7 Wall Street · 25 July 2026neutral

The article discusses Seth Klarman's Baupost Group's five largest common-stock positions as disclosed in a 13F filing for the period ending March 31, 2026, filed on May 14, 2026.

Why it matters — For ELV watchers, this matters because major institutional investors' top holdings can influence market perception and signal conviction in certain sectors or companies.

FAQ

Frequently asked questions about ELV stock

What is the ELV stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Elevance Health, Inc. have a median 12-month price target of $457, with estimates ranging from $393 to $492. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELV stock a buy right now?

Of the 22 analysts covering Elevance Health, Inc., 15 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elevance Health, Inc. 62 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELV?

As at 1 Aug 2026, Elevance Health, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (90 of 100).

Will ELV stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +19.4% from the last close, and Ticker Nerd's factor model ranks Elevance Health, Inc. 62 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELV stock forecast for 2030?

No analyst covering Elevance Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $393 to $492 over the next 12 months.

How has ELV stock performed over the past year?

Elevance Health, Inc. returned +42.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elevance Health, Inc. do?

Elevance Health, Inc. is a diversified health company headquartered in Indianapolis, Indiana.

What is the latest news on ELV?

The most recent item we track (Business Wire, 30 July 2026): "Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey". Elevance Health announced enhancements to its connected cancer care model, aimed at providing earlier support, personalized care navigation, and more coordinated care for consumers throughout their cancer journeys.

Company

About Elevance Health, Inc.

Elevance Health, Inc. is a diversified health company headquartered in Indianapolis, Indiana. The company focuses on supporting health at every life stage by integrating medical, pharmacy, behavioral, and complex-care services. Elevance Health operates through several key segments. Its Health Benefits segment provides a broad range of commercial, Medicaid, Medicare, and specialty health plans to individuals, employers, and government programs. Through CarelonRx, it offers pharmacy benefit management solutions, including prescription management and related pharmacy services. Carelon Services delivers care management, analytics, and other clinical and administrative services aimed at coordinating and improving care quality. Together, these businesses enable Elevance Health to serve as a major player in the U.S. healthcare system, connecting health plans, care providers, and consumers to streamline access to care and support better health outcomes across diverse populations.

CEO Ms. Gail Koziara Boudreaux · 96,129 employees · United States · https://www.elevancehealth.com